Induction chemotherapy with Methotrexate, Vinblastine, Epiadriamycin and Carboplatin (M-VEP) in transitional cell urothelial cancer

1991 ◽  
pp. 107-109
Author(s):  
G. Aravantinos ◽  
D. V. Skarlos ◽  
H. Linardou ◽  
C. Christodoulou ◽  
C. Deliveliotis ◽  
...  
Keyword(s):  
Induction Chemotherapy ◽  
Urothelial Cancer ◽  
Transitional Cell

scholarly journals Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial

2002 ◽  
Vol 13 (2) ◽  
pp. 243-250 ◽  
Author(s):  
D. Pectasides ◽  
J. Glotsos ◽  
N. Bountouroglou ◽  
A. Kouloubinis ◽  
N. Mitakidis ◽  
...  
Keyword(s):  
Phase Ii ◽  
Urothelial Cancer ◽  
Phase Ii Trial ◽  
Transitional Cell ◽  
Weekly Chemotherapy ◽  
Gemcitabine And Cisplatin

scholarly journals Low grade transitional cell carcinoma of the urethra successfully treated with only intraurethral instillation of Mitomycin-C

2018 ◽  
Vol 1 (2) ◽  
Author(s):  
Sharfuddeen A. Mashi ◽  
Sani A. Aji ◽  
Muzzammil Abdullahi ◽  
Bashir Yunusa ◽  
Sani U. Alhassan
Keyword(s):  
Mitomycin C ◽  
Urothelial Cancer ◽  
Transitional Cell ◽  
Significant Risk ◽  
Low Grade ◽  
Short Segment ◽  
Urinary Tract Symptoms ◽  
History Of ◽  
Posterior Urethra ◽  
Lower Urinary

Urethral cancer is very rare disease, accounting for less than 0.5% of incidences of malignancies. Data on its management are scarce due to the rare nature of the cases. We present a 34-year-old man, who presented to our hospital with a month history of hematuria. He had no lower urinary tract symptoms and no significant risk factors for urothelial cancer. He was evaluated and found to have lesions in the posterior urethra on urethrocytoscopy, biopsy of which revealed a low-grade urothelial cancer. He was counselled and had 6 courses of intraurethral instillation of 40mg of Mitomycin-C diluited in 50mL of saline held in the urethra with penile clamp for 30 minutes. The hematuria stopped after the second course, a repeat urethrocystoscopy 6 months after the completion of the chemotherapy, showed resolution of the lesion and repeat biopsy showed no evidence of malignancy. However, the patient developed short segment partial penile urethral stricture that was treated with dilatation. In conclusion, low-grade urothelial cancer of the urethra can be successfully cured with Intraurethral instillation of Mitomycin-C, without prior transurethral resection.

Gemcitabine Plus Cisplatin, an Active Regimen in Advanced Urothelial Cancer: A Phase II Trial of the National Cancer Institute of Canada Clinical Trials Group

1999 ◽  
Vol 17 (9) ◽  
pp. 2876-2876 ◽  
Author(s):  
Malcolm J. Moore ◽  
Eric W. Winquist ◽  
Nevin Murray ◽  
Ian F. Tannock ◽  
Susan Huan ◽  
...  
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Urothelial Cancer ◽  
Response Rate ◽  
Phase Ii Trial ◽  
Locally Advanced ◽  
Transitional Cell ◽  
Grade 3 ◽  
Intent To Treat ◽  
To Receive

PURPOSE: To evaluate the efficacy and toxicity of gemcitabine (2′,2′-difluorodeoxycytidine) plus cisplatin in previously untreated patients with advanced transitional-cell carcinoma. PATIENTS AND METHODS: Thirty-one patients with measurable advanced transitional-cell carcinoma who had received no prior chemotherapy for metastatic disease were scheduled to receive gemcitabine 1,000 mg/m2 intravenously over 30 minutes on days 1, 8, and 15 and cisplatin 70 mg/m2 over 1 hour on day 2 of a 28-day cycle. Prior adjuvant or neoadjuvant therapy for locally advanced disease was allowed if this was completed more than 1 year before study entry. RESULTS: There were six complete responses and 10 partial responses in 28 assessable patients, for anoverall response rate of 16 of 28 (57%). The response rate on an intent-to-treat basis was 16 of 31 patients (52%). The median survival is 13.2 months, with 18 patients still alive at this time. Toxicity was primarily hematologic, with 12 of 31 patients (39%) having ≥ grade 3 granulocytopenia and 17 of 31 (55%) having ≥ grade 3 thrombocytopenia. Two patients had febrile neutropenia. All patients required a dose modification of gemcitabine at some point in their therapy; the primary reason was thrombocytopenia and/or neutropenia. CONCLUSION: Gemcitabine plus cisplatin is an active regimen for the treatment of urothelial cancer.

The significance of urine NMP22 in the screening of urothelial cancer (comparison of ELISA and immunochromatography method)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e16024-e16024
Author(s):  
H. Ikeda ◽  
Y. Ishida ◽  
T. Dejima ◽  
M. Nomura ◽  
H. Sanefuji
Keyword(s):  
Predictive Value ◽  
Matrix Protein ◽  
Urothelial Cancer ◽  
Transitional Cell ◽  
False Negative ◽  
Local Treatment ◽  
Urine Cytology ◽  
Nuclear Matrix Protein ◽  
Sensitivity Specificity ◽  
Higher Sensitivity

e16024 Background: The early diagnosis of urothelial cancer allows for effective local treatment and optimizes the success of surgical therapy. Urine nuclear matrix protein 22 (NMP22) was introduced for the detection of transitional cell carcinoma. Add to old NMP22 (ELISA), new NMP22 (immunochromotography method : BladderChek) can be available from 2004. The objective of this study is to determine whether there are any correlation between urine NMP22 (two methods) and the grade or stage of urothelial cancer, and whether it can serve as a biochemical marker of urothelial cancer. Methods: A total of 246 patients with hematuria or followed up after TUR-BT, from March 2007 to December 2007,visited our hospital and subsequently underwent cystoscopy. The 246 patients provided voided urine samples. We immediately examined urine cytology and NMP22 (two methods). We set the cut off value on 12.0U/ml for NMP22 (ELISA). NMP22 (BladderChek) was judged by qualitative analysis. We decided that in urine cytology, classI,II,III were negative, while IV,V were positive by Papanicolaou classification. Results: Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) were 66.7 %, 98.3 %, 81.8 %, 96.3 % in urine cytology, 40.7 %, 75.9 %, 16.2 %, 91.8 % in NMP22 (ELISA), 59.3 %, 79.3 %, 24.6 %, 94.5 % in NMP22 (BladderChek). In 9 cases with false negative of urine cytology, 4 cases were picked up by NMP22 (ELISA), and 5 cases by NMP22 (BladderChek). Sensitivity of grade 1 was 33.3 % in urine cytology, while 66.7 % in NMP22 (BladderChek). By adding NMP22 (BladderChek) to urine cytology, sensitivity rose about 18 %. Conclusions: The sensitivity of urine cytology was unexpectedly high. NMP22 (BladderChek) is more useful than NMP22 (ELISA) because of higher sensitivity, specificity and advantage of simplicity, rapidity. It seems that the addition of NMP22 (BladderChek) to urine cytology is beneficial. No significant financial relationships to disclose.

Metronomic Outpatient-Based Chemotherapy with 5′-DFUR and Low-Dose Cisplatin for Conventional Platinum-Based Chemotherapy-Resistant Advanced Urothelial Cancer

2007 ◽  
Vol 1 ◽  
pp. CMO.S304
Author(s):  
Tomohiko Hara ◽  
Satoru Yoshihiro ◽  
Hideaki Ito ◽  
Kazuhiro Nagao ◽  
Chietaka Ohmi ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Large Scale ◽  
Urothelial Cancer ◽  
Transitional Cell ◽  
Eastern Cooperative Oncology Group ◽  
Metronomic Chemotherapy ◽  
World Health ◽  
Severe Toxicity ◽  
Platinum Based Chemotherapy ◽  
Advanced Urothelial Cancer

Background Metronomic chemotherapy is aimed at lessening the adverse effects of treatment while rendering cancer cells cytostatic. The oral 5-fluorouracil prodrug “5′-DFUR” has been shown to inhibit angiogenesis and is regarded as a good candidate agent for metronomic chemotherapy. Moreover, cisplatin and 5′-DFUR have been shown to synergistic cytotoxic effects. Methods We evaluated the safety and efficacy of metronomic chemotherapy using daily oral 5′-DFUR at the dose of 600 mg/day and biweekly cisplatin infusion at the dose of 20 mg/person in 23 patients with urothelial cancer resistant to conventional platinum-based chemotherapy. Results Twenty-three patients were enrolled between August 2000 and December 2004. The median survival time after the initiation of metronomic chemotherapy was 15.2 months. The 1-year, 2-year and 3-year survival rates were 55.1%, 45.1% and 5.9%, respectively. Grade 3 fatigue was observed as severe toxicity in one patient. No cases showed nephrotoxicity and adverse effects necessitating medical intervention. Conclusions Although a large-scale prospective study would be necessary before the therapy is established as a standard, our metronomic chemotherapy regimen appears to be a potentially useful palliative treatment alternative for patients with advanced urothelial cancer resistant to conventional platinum-based chemotherapy. Abbreviations M-VAC: methotrexate, vinblastine, doxorubicin, and cisplatin; GC: gemcitabine and carboplatin; 5′-DFUR: 5′-deoxy-5-fluorouridine; 5-FU: 5-fluorouracil; CDDP: cisplatin; TCC: transitional cell carcinoma; ECOG: Eastern Cooperative Oncology Group; PS: performance status; UICC: Union International Contre le Cancer; WHO: World Health Organization; NCI-CTC: National Cancer Institute Common Toxicity Criteria; CI: confidence interval; PR: partial response; NC: no change; PD: progressive disease; TP: thymidine phosphorylase; AUC: areas under the curve.

Vinflunine (VFL) treatment following induction chemotherapy with platinum combinations in patients with metastatic-advanced urothelial cancer. A single institution experience

2019 ◽  
Vol 18 (11) ◽  
pp. e3575-e3576
Author(s):  
K. Martinez Barroso ◽  
I. Garcia Carbobero ◽  
E. Martinez Moreno ◽  
B. Trujillo Alba ◽  
M. Borregón Rivilla ◽  
...  
Keyword(s):  
Induction Chemotherapy ◽  
Urothelial Cancer ◽  
Single Institution ◽  
Advanced Urothelial Cancer

Phase I study of gemcitabine and cisplatin followed by pemetrexed and gemcitabine in patients with metastatic transitional cell carcinoma of the urothelium: Preliminary results

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14550-14550 ◽  
Author(s):  
T. E. Hutson ◽  
S. Vukelja ◽  
S. Nicol ◽  
K. E. Hood ◽  
A. Delgado ◽  
...  
Keyword(s):  
Phase I ◽  
Dose Level ◽  
Phase Ii ◽  
Urothelial Cancer ◽  
Single Agent ◽  
Transitional Cell ◽  
Maximum Tolerated Dose ◽  
Metastatic Urothelial Cancer ◽  
Level I ◽  
Gemcitabine And Cisplatin

14550 Background: Pemetrexed has activity as a single agent and combined with gemcitabine (G) in platinum refractory metastatic urothelial cancer. The tolerability and activity of this new multi-targeted antifolate combined with standard platinum-based therapy is unknown. This Phase I multicenter trial was conducted in patients (pts) with metastatic TCC to determine the maximum tolerated dose (MTD) of G and cisplatin (C) followed by pemetrexed (P) and G. Methods: Cohorts of 3 to 6 pts were treated with escalating doses of G+C followed by P+G: Dose Level 0 -G+C (800+60 mg/m2) Day 1 and P+G (400+800 mg/m2) on Day 15; Dose Level I -G+C (800+70 mg/m2)/P+G (400+800 mg/m2); Dose Level II -G+C (1000+70 mg/m2)/P+G (400+1000 mg/m2); Dose Level III -G+C (1000+70 mg/m2)/P+G (500+1000 mg/m2) in a 28-day cycle. Pts received a maximum of 6 cycles of therapy; and all pts received folic acid and vitamin B12 supplements. The 3+3 standard Phase I escalation rule was used to establish the MTD. Results: A total of 10 pts have registered, 1 pt received only 1 dose and was replaced, and 9 have been treated: 3 at Dose Level 0 and 6 at Dose Level I. Of these 10 pts, 40% had Karnofsky PS of 100, and the median age was 68 years (range 58–82). One pt had a confirmed CR after 2 cycles, 1 pt at Dose Level I had a PR and received all 6 cycles, 6 pts did not finish treatment (4 pts due to toxicity and 2 pts due to PD), 1 pt at Dose Level I is continuing on therapy. Dose-limiting toxicity occurred in 2 pts at Dose Level I and included Grade 3–4 febrile neutropenia, pulmonary embolism, and diarrhea. The MTD of this triplet is Dose Level I, and the recommended Phase II dose (RP2D) is Dose Level 0. Patient accrual is continuing to further define toxicity at the RP2D. Conclusion: The addition of pemetrexed to standard gemcitabine and cisplatin as initial therapy for metastatic urothelial cancer is feasible. Toxicity of this triplet has been moderate. A Phase II trial is planned to determine the response rate, duration of response, TTP, time to treatment failure, and survival. Supported by Eli Lilly and Company, Indianapolis, IN [Table: see text]

scholarly journals A Challenging Case of Poorly Differentiated Transitional Cell Carcinoma of the Kidney

2018 ◽  
Vol 34 (4) ◽  
pp. 282-284
Author(s):  
Brittany Katsinis
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Urothelial Cancer ◽  
Transitional Cell ◽  
Imaging Features ◽  
Renal Sinus ◽  
Poorly Differentiated ◽  
History Play ◽  
Renal Sinus Fat

When describing carcinomas, poorly differentiated defines how little the tumor tissue resembles the normal tissue it came from. The origin of these types of tumors cannot be determined by histological findings alone. Imaging findings and patient history play a strong role in determining the source of the patient’s cancer. Imaging features of urothelial cancer of the renal pelvicaliceal system can be challenging for any sonographer or radiologist. When tumors are hyperechoic relative to nearby renal parenchyma, they may be obscured by the surrounding hyperechoic renal sinus fat, causing these carcinomas to be difficult to detect regardless of whether they are well defined or poorly differentiated. This case study delves into the difficulty in sonographically imaging a poorly differentiated transitional cell carcinoma without sonographic evidence of a primary circumscribed mass.

Sign in / Sign up

Export Citation Format

Share Document